XW013TBIntroduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW013TB
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW013TB is a billable ICD-10-PCS procedure code for Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. The Alphabetic Index lists this code under Rozanolixizumab-noli Monoclonal Antibody. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration of therapeutic substances, NEC.

Code Identity

ICD-10-PCS Code
XW013TB
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
Short Description
Introduce Rozanolixizumab in Subcu, Perc, New Tech 11
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/TechnologyTRozanolixizumab-noli Monoclonal Antibody
7QualifierBNew Technology Group 11

In the ICD-10-PCS Alphabetic Index

The FY 2027 ICD-10-PCS Alphabetic Index refers to XW013TB as Rozanolixizumab-noli Monoclonal Antibody. These index entries lead to this code:

Rozanolixizumab-noli Monoclonal Antibody
Direct entry for this code
New Technology, Rozanolixizumab-noli Monoclonal Antibody
Direct entry for this code
Iloprost
Leads to this code's table
RYSTIGGO(R)
Anatomy or device term that leads here
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table

To code rozanolixizumab-noli monoclonal antibody, open the FY 2027 ICD-10-PCS Alphabetic Index at Rozanolixizumab-noli Monoclonal Antibody. The entry lists XW013TB directly as a complete, billable code.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM021
Administration of therapeutic substances, NEC
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E013GC — Introduction of Oth Therap Subst into Subcu, Perc Approach

Similar Procedure Codes

Questions About XW013TB

Is XW013TB a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11 on inpatient claims from October 1, 2026 through September 30, 2027.

What is the ICD-10-PCS code for rozanolixizumab-noli Monoclonal Antibody?

The ICD-10-PCS Alphabetic Index lists Rozanolixizumab-noli Monoclonal Antibody under code XW013TB, Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11, billable on inpatient claims in fiscal year 2027.

What do the characters in XW013TB mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character T is the Device/Substance/Technology (Rozanolixizumab-noli Monoclonal Antibody); the 7th character B is the Qualifier (New Technology Group 11).